San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story and see what’s trending.

Halozyme drug tech gets company $30 million upfront, possibly hundreds of millions more
San Diego’s Halozyme Therapeutics will get $30 million upfront, with the possibility of hundreds of millions more, under a licensing agreement with a European biotechnology company announced Monday. Argenx, based in the Netherlands, is licensing Ha… […]